Analyst Ratings For NASDAQ:ONCE – Spark Therapeutics (NASDAQ:ONCE)
Today, NASDAQ:ONCE – Spark Therapeutics (NASDAQ:ONCE) stock was downgraded by Chardan Capital from Buy to Neutral with a price target of $85.00.
Some recent analyst ratings include
- 4/23/2018-Chardan Capital was Downgraded by analysts at Chardan Capital from a “Buy ” rating to a ” Neutral” rating. They now have a $85.00 price target on the stock, up previously from $80.00 .
- 4/19/2018-William Blair Reiterated Rating of Buy.
- 3/8/2018-Credit Suisse Group Reiterated Rating of Outperform .
- 2/21/2018-Sanford C. Bernstein Reiterated Rating of Buy.
- On 4/18/2018 John Furey, COO, sold 13,277 with an average share price of $82.52 per share and the total transaction amounting to $1,095,618.04.
- On 4/12/2018 John Furey, COO, sold 20,000 with an average share price of $77.51 per share and the total transaction amounting to $1,550,200.00.
- On 12/11/2017 John Furey, COO, sold 18 with an average share price of $46.33 per share and the total transaction amounting to $833.94.
- On 12/8/2017 John Furey, COO, bought 18 with an average share price of $73.48 per share and the total transaction amounting to $1,322.64.
- On 11/28/2017 Katherine A High, Insider, sold 5,000 with an average share price of $71.32 per share and the total transaction amounting to $356,600.00.
- On 11/16/2017 Stephen W Webster, CFO, sold 10,000 with an average share price of $70.14 per share and the total transaction amounting to $701,400.00.
- On 11/13/2017 Barge Joseph La, Insider, sold 5,500 with an average share price of $71.44 per share and the total transaction amounting to $392,920.00.
Recent Trading Activity for NASDAQ:ONCE – Spark Therapeutics (NASDAQ:ONCE)
Shares of NASDAQ:ONCE – Spark Therapeutics closed the previous trading session at 78.34 down -3.05 3.74% with 482794 shares trading hands.